Literature DB >> 3317849

Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer.

W M Hryniuk1, A Figueredo, M Goodyear.   

Abstract

Studies were analyzed to show the correlation of response with dose intensity of single-agent 5-fluorouracil (5-FU) against colorectal cancer, multiagent CMF (cyclophosphamide, methotrexate, 5-FU) regimens against advanced breast cancer, and adjuvant therapy in stage II breast cancer. In colorectal cancer studies, subgroups in which 5-FU was given by intravenous (IV) bolus, infusion, and orally were analyzed. One study reported delivered dose levels after reductions for toxicity. This allowed calculations of received dose intensity for the three dose levels, and comparison with projected dose intensities. The data suggest that the dose-intensity response line is steep, once a threshold dose intensity has been surpassed. An increase of only 100 mg/m2/wk of received dose intensity of 5-FU increased the response rate from 20% to 29%, which in relative terms was an increase of almost 50%. Received dose intensity may correlate with response, not only in groups of patients, but also in individual patients, and this may, in fact, be the most important application of the concept of dose intensity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317849

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  33 in total

Review 1.  Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

Authors:  W E Evans; M V Relling
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

Review 2.  Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.

Authors:  R L Poorter; P J Bakker; C H Veenhof
Journal:  Pharm World Sci       Date:  1998-04

3.  Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor.

Authors:  C Walsh; R H Blum; R Oratz; A Goldenberg; A Downey; J L Speyer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 4.  Determining the optimal dose in the development of anticancer agents.

Authors:  Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij
Journal:  Nat Rev Clin Oncol       Date:  2014-03-25       Impact factor: 66.675

5.  Correlation between tumour blood flow and fluorouracil distribution in a hypovascular liver metastasis model.

Authors:  D Burke; P Carnochan; C Glover; T G Allen-Mersh
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; A Rogatko; E M Newman; C McAleer; J Brennan; F P LaCreta; G R Hudes; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.

Authors:  D Brohée
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

8.  Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation.

Authors:  Whalen Clark; Erin M Siegel; Y Ann Chen; Xiuhua Zhao; Colin M Parsons; Jonathan M Hernandez; Jill Weber; Shalini Thareja; Junsung Choi; David Shibata
Journal:  J Am Coll Surg       Date:  2013-03-21       Impact factor: 6.113

Review 9.  Epirubicin. Clinical pharmacology and dose-effect relationship.

Authors:  J Robert
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  Response to treatment of breast cancer.

Authors:  J L Berenberg
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.